U.S. stock night market volatility: Kala Bio fell 10.58% in after-hours trading, with no significant news but showing volatility. What is causing such market sentiment?

U.S. Stock Night Market Movements Kala Pharmaceuticals fell 10.58% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Stocks with High Trading Volume in the Industry Moderna rose 0.06% in the night market. Based on recent key news: On May 11, the World Health Organization reported a hantavirus outbreak, prompting Moderna to initiate preclinical research, leading to a rise in stock price. Although the public health risk assessment is low, market enthusiasm for vaccine stocks has significantly increased, driving stock price volatility. On May 11, analysts pointed out that the commercial prospects of hantavirus are limited, and stock price fluctuations are more driven by sentiment. This incident only confirms the flexibility of Moderna's mRNA technology platform. On May 11, Moderna's stock price made a strong comeback, rebounding approximately 50% from recent lows. Improved momentum and market optimism regarding the mRNA pipeline have driven the stock price up. The biotechnology sector shows improved momentum, and market sentiment is optimistic. BeiGene fell 0.54% in the night market. Based on recent key news: On May 12, analysts raised the 2026 EPS estimate for BeOne Medicines Ltd. to $6.25, with a target price of $412. This adjustment reflects market confidence in the company's future profitability and may have a positive impact on the related industry. On May 11, Citibank updated its model for BeOne Medicines Ltd., reflecting the latest earnings guidance, raising the target price from $430 to $453, and giving it a buy rating. This move shows market recognition of the company's long-term growth potential, which may drive the stock price up. On May 8, BeOne Medicines Ltd.'s management believes that even if uMRD may not serve as an approvable endpoint, data with fixed treatment regimens (VO) may provide potential differentiation. This information may affect investors' expectations for the company's future development. The U.S. stock market has seen increased volatility recently, warranting attention. GRAIL fell 0.45% in the night market. Based on recent key news: On May 13, ASCO data is expected to validate GRAIL's significant clinical efficacy and promote further adoption. FDA and CMS reviews are proceeding as planned, with strong commercial growth and high physician engagement driving stock price volatility. Source: MarketBeat On May 11, analysts rated GRAIL as hold, not included in the top recommended stocks list, and the market is taking a wait-and-see attitude towards its future performance, affecting the stock price. Source: MarketBeat On May 10, The Motley Fool recommended GRAIL, and although analysts hold a neutral stance, the market still has expectations for its potential growth opportunities. Source: The Motley Fool The industry is experiencing strong growth, with high physician engagement